Cargando…
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
SIMPLE SUMMARY: Human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) represents a distinct entity with molecular, pathological, and clinical features that lead to an improved response to standard therapy and a favorable prognosis compared to HPV-negative HNSCC. In this r...
Autores principales: | Julian, Ricklie, Savani, Malvi, Bauman, Julie E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656769/ https://www.ncbi.nlm.nih.gov/pubmed/34884999 http://dx.doi.org/10.3390/cancers13235889 |
Ejemplares similares
-
Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer
por: Rao, Yuan James, et al.
Publicado: (2023) -
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022) -
Immunotherapy of HPV-associated head and neck cancer: Critical parameters
por: Nizard, Mevyn, et al.
Publicado: (2013) -
HPV Associated Head and Neck Cancer
por: Spence, Tara, et al.
Publicado: (2016) -
DNA Methylation and HPV-Associated Head and Neck Cancer
por: Nakagawa, Takuya, et al.
Publicado: (2021)